13G Filing: Brookside Capital and Immune Design Corp. (IMDZ)

Page 6 of 7 – SEC Filing

(iv)
Shared power to dispose or to direct the disposition of: 0.Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that
purpose or effect.CUSIP No. 45252L103

13G

Page 7 of 8After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement
is true, complete and correct.
Dated: October 6, 2017

BAIN CAPITAL PUBLIC EQUITY MANAGEMENT, LLC

By:
Name: Joshua Ross
Title: Managing Director

BROOKSIDE CAPITAL INVESTORS II, L.P.
By: Bain Capital Public Equity Management, LLC,
its general partner
By:
Name: Joshua Ross
Title: Managing Director

BROOKSIDE CAPITAL TRADING FUND, L.P.
By: Brookside Capital Investors II, L.P.,
its general partner
By: Bain Capital Public Equity Management, LLC,
its general partner

By:
Name: Joshua Ross
Title: Managing Director

Follow Immune Design Corp. (NASDAQ:IMDZ)